According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.

Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.

‘Without an adequate amount of thyroid hormone mothers can be exposed to hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, which affect around 10% of pregnant women and are the leading causes of maternal and neonatal mortality worldwide. Mothers who suffer from hypertensive disorders during pregnancy are at increased risk of long-term cardiovascular consequences and hypertensive disorders in subsequent pregnancies. Evidence also indicates a risk of reduced cognitive ability to their offspring.

‘Knowing if you are genetically predisposed to Hashimoto’s or Graves’ Diseases, which are both thyroid autoimmune disorders is important to be aware of, to ensure all appropriate tests are ordered. Autoimmune disorders may predispose mothers to a thyroid problem during pregnancy’, says Professor Creswell Eastman, who also serves as the ATF’s Principal Medical Advisor.